Januvia, a medication for type 2 diabetes, saw its shipments total $2.7 billion in the first nine months of 2023 [1]. This represents a decrease from the same period in 2022, when shipments reached $3.5 billion [1].
How is Januvia performing financially?
In the first nine months of 2023, Januvia's shipments generated $2.7 billion [1]. This figure is lower than the $3.5 billion recorded for the same timeframe in 2022, indicating a decline in sales [1].
What is Januvia used for?
Januvia is a prescription medication used along with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus [2].
When does Januvia's patent expire?
Information regarding Januvia's patent expiration is available through patent tracking services. DrugPatentWatch.com provides data on drug patents, including expiry dates, which can indicate when generic versions may become available [3].
Can generic versions of Januvia be sold?
The availability of generic versions of Januvia depends on patent expirations and regulatory approvals. Once key patents expire, other manufacturers may seek approval to market generic equivalents, potentially increasing competition and affecting market dynamics. Information on patent status can help determine when this may occur.